IL-ADTALEM
17.8.2020 08:02:09 CEST | Business Wire | Press release
ACAMS, in partnership with artificial intelligence (AI) company ElephantThink, has successfully conceptualized and delivered its first fully online web-based compliance training program for Dutch banking group ING. The training partnership is for a multi-lingual SaaS solution offering mobile and web-based access to equip recipients with core competencies required to perform analysis, onboarding and anti-money laundering prevention roles and considered pioneering in the world of financial crime prevention training.
ING, which has a presence in over 40 countries serving over 38 million customers, places great emphasis on compliance, know your customer (KYC) / customer due diligence (CDD) and enhanced due diligence (EDD), which is reflected in the 4-year training agreement with ACAMS and ElephantThink.
Under the terms of the partnership, training is delivered digitally via e-learning on the ElephantThink Smart Learning Platform, and accessible in nine languages - English, Dutch, French, German, Italian, Romanian, Spanish, Turkish and Polish. Learners will have the ability to access the web-based learning curriculum supported by a companion mobile application which includes gamification elements to drive engagement and information retention. Qualifying ING employees will receive a verifiable digital certificate upon completion of their training.
Commenting on the training partnership, Roel Louwhoff, chief operations officer and chief transformation officer of ING, said: “As a gatekeeper to the financial system, ING has a responsibility to protect it, our customers and society against financial and economic crimes. Partnering with ACAMS to introduce their internationally recognized and certified digital training enables us to further enhance the KYC knowledge, skills and expertise of our employees in an innovative and engaging manner. This helps to fight financial economic crime, ensuring our customers can continue banking safely and securely as we empower them to stay a step ahead in life and in business.’’
Angela Salter, Interim President of ACAMS, said, “This is our first foray into delivering global web-based training to the KYC / CDD and transaction monitoring (TM) teams, and the promise of accelerated reach and efficacy is especially significant in the current environment. The commitment of ING to support a revolutionary training approach for a highly regulated and constantly evolving operating landscape cemented the success of our ground-breaking partnership with ElephantThink.”
Jack Smies, CEO of ElephantThink, said, “The mix of very high quality content from our partner ACAMS combined with our capabilities on AI, gamification and digital claims can really turbo charge people’s learning, which is reflected in the initial response and results of the training.”
Under the terms of the partnership ACAMS will make available AML, Sanctions, KYC and Transaction Monitoring programmes as well as ACAMS Certified Know Your Customer Associate (CKYCA) training at foundational and intermediate levels. These trainings are available in English, Dutch and multiple other languages, providing front-line and operations teams with the tools to perform KYC, CDD and EDD duties. ING’s sanctions, AML compliance and audit team learners will also have access to the full suite of ACAMS courses for the 2nd and 3rd lines of defence, underpinned by ACAMS’ comprehensive continuous education and alerts programme.
In a separate development, ACAMS has been granted approval by the Netherlands training registry body CRKBO to provide anti-financial crime training on a VAT free basis in the country, representing a savings of 21% on every ACAMS training course procured direct from ACAMS including its gold-standard CAMSTM Certified AML Specialist and recently launched Certified Global Sanctions Specialist (CGSS) qualifications.
About ACAMS®
ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a leading workforce solutions provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime prevention professionals from a wide range of industries. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Its new Certified Global Sanctions Specialist (CGSS) certification commenced in January 2020. Visit acams.org for more information.
About Adtalem Global Education
The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal ) and LinkedIn .
About ElephantThink:
ElephantThink is an Artificial Intelligence company that focuses on algorithms and models. By applying this specifically to employee training and development they created a Smart Learning Platform. This smart learning platform can provide hyper personalization so that the learning is optimized for maximum efficiency per individual learner and is unique in that it adapts to the specific way each participant learns. By using spaced repetition of learning elements that are memory dependent, gamification to ensure user engagement and verifiable certificates and badges for user motivation and recognition ET is able to significantly improve the learner’s development. Visit elephantthink.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom